Self Efficacy, Walking Ability, Gait Speed and Physical Activity in People With Chronic Lung Disease

Completed

• Conditions: Chronic Lung Disease; Self-efficacy

• Registration Number: NCT01583595
• Lead Sponsor: Mayo Clinic

Brief Summary

Most patients with chronic lung disease underestimate their actual walking ability due to low confidence. To better understand the relationships between lung function, self-efficacy for walking (confidence in ability to walk a defined distance), actual walking ability for the same distance gait speed and physical activity level-PAL- (total energy expenditure/resting metabolic rate).

Quality of life, self efficacy for activity questionnaires, physical activity level measurement, 4-meter gait speed and 6-minute walk distance will be measured.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-12
• Study First Submitted: 2012-02-07
• Study First Submitted QC: 2012-04-23
• Study First Posted: 2012-04-24
• Primary Completion: 2012-07
• Study Completion: 2012-07
• Status Verified: 2013-03
• Last Update Submitted: 2013-04-01
• Last Update Posted: 2013-04-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• Men and women 40 years and older
• Diagnosis of any chronic lung disease as evidenced by pulmonary function testing completed within the prior 12 months
• Able to walk independently and successfully complete the 6-minute walk assessment

Read More

Exclusion Criteria

• Unable to walk without assistance or complete the 6-minute walk assessment
• Patients unable to comprehend and accurately respond to the study questionnaires either by written or spoken communication
• Patients diagnosed with or treated for a lower respiratory tract infection or COPD exacerbation within the prior 30 days

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Analyze associations between self-efficacy for walking, gait speed, physical activity level and perceptions of symptoms in patient with chronic lung disease (COPD and Pulmonary Fibrosis)	Day of enrollment.	Correlation , regression models and mediation analysis (self efficacy and physical activity) will be performed.

Secondary Outcome Measures

Name	Time	Method
Predictive utility of 4-meter gait speed for estimating physical activity level (PAL) as validated by gold standard activity monitor.	1 week	Measure 4-meter gait speed during standardized 6 mintute walk test and compare to armband activity monitor results to determine predictive ability, if any, on PAL in people with chronic lung disease.

Trial Locations

Locations (1)

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States